Experimental evidence also supports the use of dipeptidyl peptidase-4 inhibitors or gliptins as potential drugs to prevent cognitive impairment through the preservation of Glucagon-like peptide 1 (GLP-1) function and increasing neurogenesis, among many other mechanisms [90]. This evidence concerns the gene DPP4 and Cognitive impairment.